No annual revenue total was found in Sana Biotechnology, Inc.'s SEC filings.
Sana Biotechnology, Inc. (SANA) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). Free cash flow was -$144.8 million. As of Jun 30, 2026 it held $160.5 million in cash and investments and $73.7 million in total debt.
Revenue
—
Net income (TTM)
$-211.82M
+16.0% vs year-ago TTM
Operating cash flow (TTM)
$-132.24M
+26.8% vs year-ago TTM
Free cash flow (TTM)
$-135.06M
+27.1% vs year-ago TTM
EPS (TTM)
$-0.76
+28.2% vs year-ago TTM
Dividend per share
None
Shares outstanding
266.87M
+18.6% vs prior year
Net cash
$86.75M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- SANA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Seattle, WA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1770121
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$250.3M | -$272.7M | -$293.1M | -$272.6M | -$356.9M |
| Net income | -$244.2M | -$266.8M | -$283.3M | -$269.5M | -$355.9M |
| Diluted EPS | -$0.96 | -$1.16 | -$1.46 | -$1.43 | — |
| Operating cash flow | -$143.8M | -$223.2M | -$253.6M | -$290.1M | -$251.1M |
| Free cash flow | -$144.8M | -$256.6M | -$273.6M | -$310.9M | -$280.9M |
| Total assets | $416.9M | $501.0M | $565.3M | $822.7M | $1.1B |
| Total liabilities | $256.0M | $250.5M | $277.8M | $323.4M | $400.9M |
| Stockholders' equity | $160.9M | $250.5M | $287.5M | $499.3M | $728.5M |
| Cash and investments | $138.4M | $152.5M | $205.2M | $434.0M | $746.9M |
| Total debt | $78.9M | $94.2M | $104.1M | $108.3M | $110.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Sep 8, 2026 | Sep 8, 2026 |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2026 | Aug 10, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 5, 2026 | Jun 4, 2026 |
| 8-K |
Current report
Other events
|
May 15, 2026 | May 15, 2026 |
| 10-Q | Quarterly report | May 11, 2026 | Mar 31, 2026 |
All 389 Sana Biotechnology, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.